Truist Securities Maintains Buy on Viridian Therapeutics, Lowers Price Target to $33

Benzinga Newsdesk www.benzinga.com Negative 50.9%

Neg 50.9% Neu 0% Pos 0%

Truist Securities analyst Gregory Renza maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $36 to $33.